Zileuton (sodium)
Modify Date: 2024-01-11 06:20:54
Zileuton (sodium) structure
|
Common Name | Zileuton (sodium) | ||
|---|---|---|---|---|
| CAS Number | 118569-21-4 | Molecular Weight | 258.27200 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C11H11N2NaO2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Zileuton (sodium)Zileuton sodium is a potent and selective inhibitor of 5-lipoxygenase, exhibiting inflammatory activities. |
| Name | N-hydroxy-N-(1-benzo[b]thien-2-ylethyl) urea sodium salt |
|---|---|
| Synonym | More Synonyms |
| Description | Zileuton sodium is a potent and selective inhibitor of 5-lipoxygenase, exhibiting inflammatory activities. |
|---|---|
| Related Catalog | |
| In Vitro | In anti-CD3-treated cells, IL-2 decreases in zileuton-treated and untreated cells with increasing incubation time. Zileuton likely reduces IL-2 levels by inhibiting 5-lipoxygenase, hence leukotriene B4 production, an IL-2 inducer[2]. |
| In Vivo | In zileuton (5 mg/kg, p.o.) treated I/R rat, the effect of zileuton to decrease NF-κB expression does not change significantly in the presence of COX inhibitors, and the group reveals significantly lower level of NF-κB staining. Zileuton (5 mg/kg, p.o.) treatment given to I/R rats decreases apoptotic index significantly. Zileuton has no significant effect on increased serum TNF-α levels in I/R group[1]. Zileuton (1200 mg/kg) inhibits the polyp formation in APCΔ468 colon and small intestine. Zileuton treatment inhibits the proliferation rates of non epithelial cells in polyps, and increases the apoptosis rates in polyps in rat. There is significant increase in the number of apoptotic cells in the Zileuton-treated cells both in small intestine and in the colon. The reduced proliferation rate may significantly contribute to the reduction of polyposis in both the small intestine and colon of Zileuton-fed APCΔ468 mice[3]. |
| Animal Admin | Rats: Rats are randomized into 6 groups (n=12 per group): sham I/R group, I/R group, zileuton+I/R group, zileuton+indomethacin+I/R group, zileuton+ketorolac+I/R group, and zileuton+nimesulide+I/R group. 5-LOX inhibitor zileuton (5 mg/kg, orally twice daily) is given alone or with non-selective COX inhibitor indomethacin (5 mg/kg, intraperitoneally), selective COX-1 inhibitor ketorolac (10 mg/kg, orally) or selective COX-2 inhibitor nimesulide (10 mg/kg, subcutaneously). COX inhibitors are given 15 minutes before zileuton administration. All drugs are given for 3 days prior to I/R or sham I/R procedure. Dose of zileuton (5 mg/kg, twice daily) is used in this study. Rats in sham I/R group receive the vehicle of zileuton orally. Zileuton is dissolved in dimethyl sulfoxide (DMSO) and further dilutions are made using saline to achieve a final DMSO concentration of 1%. |
| References |
| Molecular Formula | C11H11N2NaO2S |
|---|---|
| Molecular Weight | 258.27200 |
| Exact Mass | 258.04400 |
| PSA | 97.63000 |
| LogP | 3.54110 |
| Storage condition | 2-8℃ |
| Zileuton (sodium) |